Design optimization and characterization of Her2/neu-targeted immunotoxins: Comparative in vitro and in vivo efficacy studies

Oncogene

Volumn 33, Issue 4, 2014, Pages 429-439

  Cao, Y ^a   Marks, J W ^a   Liu, Z ^a   Cheung, L H ^a   Hittelman, W N ^a   Rosenblum, M G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Design optimization; Gelonin; Her2 neu; Immunotoxin; Valency

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; TRASTUZUMAB RECOMBINANT GELONIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ERBB2 PROTEIN, HUMAN; GEL PROTEIN, GELONIUM MULTIFLORUM; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RIBOSOME INACTIVATING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; GENE CONSTRUCT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; SYNTHESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897018652     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.612     Document Type: Article

References (41)

1. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001; 12(Suppl 1): S81-S87.
2. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov 2009; 4: 9-18.
3. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15: 7479-7491.
4. Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 2010; 24: 410-415.
5. Brinkmann U. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. In Vivo 2000; 14: 21-27.
6. Jain KK. Use of bacteria as anticancer agents. Expert Opin Biol Ther 2001; 1: 291-300.
7. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM et al. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 1991; 51: 5361-5369.
8. Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F et al. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 1993; 168: 228-232.
9. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109: 170-179.
10. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res 2007; 13: 1374-1382.
11. Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis 2000; 11: 113-124.
12. Pennell CA, Erickson HA. Designing immunotoxins for cancer therapy. Immunol Res 2002; 25: 177-191.
13. Mazor Y, Noy R, Wels WS, Benhar I. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett 2007; 257: 124-135.
14. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 2003; 5: 44-51.
15. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001; 81: 93-124.
16. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford III WF, Houston LL et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599-1605.
17. Bera TK, Onda M, Brinkmann U, Pastan I. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. J Mol Biol 1998; 281: 475-483.
18. Bera TK, Viner J, Brinkmann E, Pastan I. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res 1999; 59: 4018-4022.
19. Yee ST, Okada Y, Ogasawara K, Omura S, Takatsuki A, Kakiuchi T et al. MHC class I presentation of an exogenous polypeptide antigen encoded by the murine AIDS defective virus. Microbiol Immunol 1997; 41: 563-570.
20. Rosenblum MG, Cheung LH, Liu Y, Marks III JW. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003; 63: 3995-4002.
21. Hossann M, Li Z, Shi Y, Kreilinger U, Buttner J, Vogel PD et al. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis. Protein Expr Purif 2006; 46: 73-84.
22. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
23. Hermanto U, Zong CS, Wang LH. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 2001; 20: 7551-7562.
24. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-3212.
25. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999; 5: 2311-2315.
26. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al. Trastuzumab- induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-3916.
27. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009; 36: 81-93.
28. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties. Breast Cancer Res 2011; 13: R123.
29. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
30. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5: 865-874.
31. Benhar I, Pastan I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin Cancer Res 1995; 1: 1023-1029.
32. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a singlechain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.
33. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-7032.
34. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009; 69: 8987-8995.
35. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012; 11: 143-153.
36. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-1412.
37. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D et al. Prospect for anti-her2 receptor therapy in breast cancer. Anticancer Res 2006; 26: 715-722.
38. Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stocklin E, Wels W et al. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998; 58: 2661-2666.
39. Azemar M, Djahansouzi S, Jager E, Solbach C, Schmidt M, Maurer AB et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003; 82: 155-164.
40. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992; 52: 6310-6317.
41. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF- 10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.